Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis.
Increasing evidence indicates that the neutrophil to lymphocyte ratio (NLR) is a useful biomarker of long-term outcomes in patients with cholangiocarcinoma. However, the prognostic role of NLR in patients with cholangiocarcinoma remains unclear. Thus, the current meta-analysis was undertaken to clarify the correlation between NLR and overall survival (OS) in cholangiocarcinoma, and a comprehensive literature research was conducted to understand the association of NLR and prognosis of cholangiocarcinoma. The hazard ratio (HR) with 95% confidence interval (CI) was used to assess OS. The synthesized HR of 1.449 (95% CI: 1.296-1.619, P < 0.001) indicated that a high NLR had an unfavourable effect on OS. Overall, this meta-analysis suggested that elevated preoperative NLR is associated with poorer rates of survival in cholangiocarcinoma patients.
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
De-Wen
DW
Tan
Department of Head and Neck Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yan
Y
Fu
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
Qi
Q
Su
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
Ming-Jun
MJ
Guan
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
Po
P
Kong
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
Sheng-Qiang
SQ
Wang
Department of General Surgery, Shengjing Hospital Affiliated with China Medical University, Shenyang, Liaoning 110004, China.
He-Ling
HL
Wang
D001650:Bile Duct Neoplasms / Q000097:blood / Q000401:mortality; D014408:Biomarkers, Tumor / Q000097:blood*; D018281:Cholangiocarcinoma / Q000097:blood / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D009504:Neutrophils; D015996:Survival Rate
D014408:Biomarkers, Tumor
Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1047-54
25051217
Oncologist. 2014 Jan;19(1):51-60
24309979
Med Oncol. 2014 Jan;31(1):787
24310810
Stat Med. 1998 Dec 30;17(24):2815-34
9921604
J Am Coll Surg. 1998 Oct;187(4):365-72
9783782
Eur J Cancer. 2014 Jun;50(9):1581-9
24630393
J Gastroenterol. 2016 Feb;51(2):153-61
26187429
Tumour Biol. 2015 Jul;36(7):5283-9
25672606
J Clin Invest. 2010 Apr;120(4):1151-64
20237412
Anticancer Res. 2016 Jan;36(1):403-8
26722073
Pancreatology. 2013 Sep-Oct;13(5):534-8
24075520
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
Immunity. 2004 Aug;21(2):137-48
15308095
Gastroenterology. 2005 May;128(6):1655-67
15887157
Br J Surg. 2001 Jul;88(7):969-74
11442529
Biometrics. 2000 Jun;56(2):455-63
10877304
Science. 2011 Mar 25;331(6024):1565-70
21436444
J Gastrointest Surg. 2013 May;17(5):913-24
23319395
Cancer Cell. 2004 Nov;6(5):447-58
15542429
Hepatology. 2001 Jun;33(6):1353-7
11391522
Cancer Immunol Immunother. 2016 Feb;65(2):141-50
26728479
Br J Cancer. 2013 Jul 9;109(1):24-8
23799846
Nature. 2001 May 17;411(6835):380-4
11357146
Sci Rep. 2015 Jul 24;5:12493
26205001
J Surg Oncol. 2008 May 1;97(6):513-8
18335453
J Hepatobiliary Pancreat Surg. 2003;10(4):259-64
14598144
J Natl Cancer Inst. 2014 May 29;106(6):dju124
24875653
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Cancer Immunol Immunother. 2011 Jun;60(6):819-27
21373990
World J Gastroenterol. 2010 Dec 14;16(46):5790-800
21154999
Sci Rep. 2015 Jul 31;5:11026
26226887
Semin Liver Dis. 2004 May;24(2):115-25
15192785
Gut. 2012 Dec;61(12 ):1657-69
22895392
J Am Coll Surg. 2001 Oct;193(4):384-91
11584966